Novo Nordisk has been made gold with Ozempic but knows that it will not last forever. So you already have two substitutes

The slimming drug market does not stop enlarging but the competition for taking the largest portion in this growing “cake” It is fierce. The American pharmaceutical Ozempic. Now the European company tries to recover its advantage.

And he does it with a double ad.

Roadmap. Little by little Let’s get to know more details About the drugs that Danish pharmaceuticals Novo Nordisk wants to give relief to Ozempic and Wegovy, their star treatments based on semaglutida.

Different compounds, different analogues. Semaglutida is the active compound on which medications such as Ozempic and Wegovy are based. This formula, initially devised as diabetes treatment, works by serving as analogous to the GLP-1 hormone (peptide similar to type 1 glucagon), it is what is known as an agonist of hormone receptors.

LPG-1 is a hormone that fulfills two functions in our body by transmitting the message that we have fed on the pancreas, activating insulin production; and to the brain, unleashing the feeling of satiety. This second function is the one that has led to the success of Ozempic and similar drugs transforming into weight loss treatments and thus achieving its present success.

The new Danish pharmaceutical formulas are based on compounds that act similarly to the semaglutida, but with characteristics that make them own and, at least in principle, superior.

Cagrisema Of the formulas proposed by Novo Nordis, Cagrisema is perhaps the one in a more advanced state of development. The drug is based on the semaglutida and the Cagrilintidaa compound that serves as an analogue of amiline And also of the Calcitoninacting as agonist of some of the receptors of these hormones.

Amiline is a hormone similar to insulin, also segregated by the pancreas and also used for glycemic control in our body. Cagrisema therefore works as a double (or triple) analogous, however The first results They were not as positive as some expected.

New data. Now we have the remaining data of the essays by the company to derter the efficacy of the drug. According to Explain Reutersthe study data showed a weight reduction of about 23% in overweight adults after 68 weeks; and 16% weight loss among people with diabetes.

Those responsible for the company gave data on moderate adverse effects, which affected 79.6% of the participants; and serious, which affected 9.8% (with 6% of patients abandoning the trial). Those responsible expect the arrival of Cagrisema to the market towards the beginning of 2027.

Amicretin. Last week Novo Nordisk He also announced The implementation of phase 3 tests of amicretin, one of the compounds designed to contain the legacy of the semaglutida. According to the company itself, this compound is a unimolecular agonist of prolonged action of the GLP-1 receptors and those of the amiline.

One of the great novelties is that this formula is being tested not only to evaluate its subcutaneous administration but also its consumption orally. Phase 3 of clinical trials usually seeks to complete and complement the information obtained in previous trials in addition to studying additional issues such as dosage or efficiency compared to other formulas.

The other novelty of Novo. In addition to the new formulas, Ozempic has also monopolized attention in the last week. He did it since the European Medicines Agency (EMA) I went on to recommend this drug as treatment for peripheral arterial disease,

In Xataka | Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada

Image | Chemist4u / News Oresund